Generate Biomedicines Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 31.07, 34.5, 122.97, 22.5, 163.2 ], "ebit_estimate": [ -273.19, -292.82, -262.24, -394, -359.8 ], "ebitda_estimate": [ -255.64, -294.94, -211.17, null, null ], "net_income_estimate": [ -270.97, -291.16, -256.83, -401.5, -367.3 ], "per_share_eps_estimate": [ -2.37, -2.28, -2.36, -2.81, -2.45 ], "eps_nri_estimate": [ -2.21, -2.07, -1.35, -1.97, -1.61 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.14, 3.34, 2.83, null, null ], "pretax_income_estimate": [ -259.56, -279.6, -220.07, -315, -277.2 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -89.17, -56.98, -51.74, null, null ], "gross_margin_estimate": [ null, null, null, 85, 85 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 13.89, "long_term_revenue_growth_rate_mean": "51.49", "future_per_share_eps_estimate_growth": -1.93, "future_eps_nri_estimate_growth": 13.89, "future_revenue_estimate_growth": 51.49, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -8.06, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202603", "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 5.94, 6.63, 7.81, 8.81, 2.5, 3.25, 3.75, 4.42 ], "ebit_estimate": [ -59.75, -67.37, -73.08, -73.17, -75.36, -74.25, -74.75, -75.47 ], "ebitda_estimate": [ -63.71, -64.5, -71.5, -77, null, null, null, null ], "net_income_estimate": [ -53.62, -69.35, -74.8, -76.45, -72.98, -71.87, -72.37, -73.09 ], "per_share_eps_estimate": [ -0.54, -0.57, -0.63, -0.67, null, null, null, null ], "eps_nri_estimate": [ -0.5, -0.5, -0.54, -0.54, -0.52, -0.49, -0.49, -0.49 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -53.62, -64.03, -71.44, -69.77, -72.98, -71.87, -72.37, -73.09 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 13.89, "long_term_revenue_growth_rate_mean": "51.49", "future_per_share_eps_estimate_growth": -1.93, "future_eps_nri_estimate_growth": 13.89, "future_revenue_estimate_growth": 51.49, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -8.06, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }